Steroid therapy of chronic hepatitis: Characteristics associated with response in anti-hepatitis C virus-positive and -negative patients

American Journal of Gastroenterology

Volumn 91, Issue 2, 1996, Pages 300-308

  Thiele, Dwain L ^a   DuCharme, Louise ^b   Cunningham, Muriel R ^b   Mimms, Larry T ^b   Cuthbert, Jennifer A ^b   Lee, William M ^b   Combes, Burton ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISOLONE;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; FEMALE; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEROID THERAPY;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BASE SEQUENCE; DNA PRIMERS; ENZYME TESTS; FEMALE; GLUCOCORTICOIDS; HEPACIVIRUS; HEPATITIS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS, CHRONIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PREDNISOLONE; PREDNISONE; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE; RETROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS;

EID: 0030064689     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;158: 159-85.
2. Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
3. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;i:735-7.
4. Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 1984;4:1-12.
5. Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85:713-7.
6. Keating JJ, O'Brien CJ, Stellon AJ, et al. Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: An analysis of 204 patients. Q J Med 1987;62:59-66.
7. Galbraith RM, Portman B, Eddleston ALWF, et al. Chronic liver disease developing after outbreak of HBsAg-negative hepatitis in haemodialysis unit. Lancet 1975;ii:886-90.
8. Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
9. McFarlane IG, Smith HM, Johnson PJ, et al. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result? Lancet 1990;i:754-7.
10. Lenzi M, Johnson PJ, McFarlane IG, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 1991;338:277-80.
11. Czaja AJ, Taswell HF, Rakela J, et al. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. Mayo Clin Proc 1991;66:572-82.
12. Garson JA, Lenzi M, Ring C, et al. Hepatitis C viraemia in adults with type 2 autoimmune hepatitis. J Med Virol 1991;34:223-6.
13. Todros L, Touscoz G, D'Urso N, et al. Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders. J Hepatol 1991;13:128-31.
14. Magrin S, Craxi A, Fiorentino G, et al. Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol 1991;13:56-60.
15. Magrin S, Craxi A, Fabiano C, et al. Hepatitis C virus replication in "autoimmune" chronic hepatitis. J Hepatol 1991;13:364-7.
16. Lunel S, Abuaf N, Frangeul L, et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992;16:630-6.
17. Nishiguchi S, Kuroki T, Ueda T, et al. Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med 1992;116:21-5.
18. Vallari DS, Jett BW, Alter HJ, et al. Serological markers of posttransfusion hepatitis C viral infection. J Clin Microbiol 1992;30:552-6.
19. Bukh J, Purcell RH, Miller RH. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci USA 1992;89:187-91.
20. Hosmer DW, Lemeshow S. Stepwise logistic regression. In: Hosmer DW, ed. Applied logistic regression. New York: John Wiley and Sons, 1989:106-17.
21. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
22. Summerskill WHJ, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: Dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-83.
23. Davis GL. Hepatitis C virus antibody in patients with chronic autoimmune hepatitis: Pitfalls in diagnosis and implications for treatment. Mayo Clin Proc 1991;66:647-50.
24. Shiffman ML. Autoimmune hepatitis, hepatitis C, and interferon: Look before you leap. World Lit Rev 1992;87:1059-60.
25. Black M. Alpha-interferon treatment of chronic hepatitis C: Need for accurate diagnosis in selected patients. Ann Intern Med 1992;116: 86-8.
26. Ammon HV. Assessment of treatment regimens. In: Czaja AJ, Dickson ER, eds. Chronic active hepatitis. The Mayo Clinic experience. New York: Marcel Dekker, Inc., 1986: 33-46.
27. Mackay IR. Genetic aspects of immunologically mediated liver disease. Semin Liver Dis 1984;4:13-25.
28. Manns M. Autoantibodies and antigens in liver diseases, updated. J Hepatol 1989;9:272-80.
29. Fried MW, Draguesku JO, Shindo M, et al. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci 1993;38:631-6.
30. Saracco G, Touscoz A, Durazzo M, et al. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol 1990;11:339-43.